Open an account

NewAmsterdam Pharma Company NV

NAMS · NASDAQ

$21.50+$1.03 (+5.03%)TodayMarket closed ·
Prev close $20.47

About NAMS

NewAmsterdam Pharma Co. NV is a clinical-stage biopharmaceutical company, which engages in the development of oral, non-statin medicine for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol. The company is headquartered in Naarden, Noord-Holland and currently employs 100 full-time employees. The company went IPO on 2022-11-23. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The firm is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The firm is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The firm strives to offer its products around the world.

Employees
100
Headquarters
Naarden, Noord-Holland
Listed
Nov 23, 2022
Sector
Health Care
Industry
Biotechnology
Website
ir.newamsterdampharma.com

NAMS key statistics

Market cap
2.57B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.62M
Volume
1.08M
Open price
$20.57
High today
$21.94
Low today
$20.36
52 Week high
$42.21
52 Week low
$19.58

NewAmsterdam Pharma Company NV (NAMS) at a glance

NewAmsterdam Pharma Company NV (NAMS) last traded at $21.50, with a market cap of 2.57B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $20.36 and $21.94. The current price is 5.6% above the day's low and 2.0% below its high.

Volume so far is 1.08M shares, below the average of 1.62M shares a day.

Over the past year NewAmsterdam Pharma Company NV has ranged from $19.58 to $42.21, and now sits 8% of the way up that range.

NewAmsterdam Pharma Company NV met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.52 per share against an estimate of -$0.4979.

The average analyst price target is $52.84, 145.7% above the current price, from 6 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

83%of 6 analyst ratings say Buy
  • Buy83.3%
  • Hold16.7%
  • Sell0.0%
Price target · 17 analystsAvg $52.84
Low
$38.38
Now
$21.50
High
$63.00

NAMS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 46.7% on average.

  1. Q3 FY24: reported -$0.18 per share against an estimate of -$0.5094
  2. Q4 FY24: reported -$0.93 per share against an estimate of -$0.4957
  3. Q1 FY25: reported -$0.34 per share against an estimate of -$0.4975
  4. Q2 FY25: reported -$0.15 per share against an estimate of -$0.5015
  5. Q3 FY25: reported -$0.61 per share against an estimate of -$0.4041
  6. Q4 FY25: reported -$0.62 per share against an estimate of -$0.3928
  7. Q1 FY26: reported -$0.40 per share against an estimate of -$0.502
  8. Q2 FY26: reported -$0.52 per share against an estimate of -$0.4979

NAMS news

  • Avi Kapoor

    Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session

  • Press releasePRNewswire

    Caristo Chosen by Leading Pharma Company as Worldwide Imaging Core Lab to Measure Coronary Plaque and Inflammation

  • Press releasePRNewswire

    Piramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal's Sellersville, Pennsylvania Site

  • Press releaseBusiness Wire

    Frazier Life Sciences Closes Oversubscribed $1.3 Billion Venture Fund

  • 'Biotech Says Its Cholesterol Drug Shows Signs Of Preventing Alzheimer's; NewAmsterdam Pharma Hopes Medicine Born Out Of Big Failures May Have An Unexpected Benefit' - STAT News

  • The Analyst Verdict: NewAmsterdam Pharma Co In The Eyes Of 6 Experts

  • Avi Kapoor

    Why ZoomInfo Technologies Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket

  • Press releasePRNewswire

    Menarini Group announces Positive Topline Data from Pivotal Phase 3 BROADWAY & TANDEM Clinical Trials Evaluating Obicetrapib and the Fixed-Dose Combination Obicetrapib with Ezetimibe 10 mg

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.